Posted innews Rheumatology
FcRn blockade with nipocalimab reduces disease activity in moderate‑to‑severe Sjögren’s syndrome: positive phase 2 DAHLIAS results
In DAHLIAS, intravenous nipocalimab 15 mg/kg every 2 weeks for 22 weeks significantly reduced ClinESSDAI scores versus placebo in anti‑Ro seropositive patients with moderate‑to‑severe Sjögren’s disease, with a safety profile similar to placebo.